TLDR
- Oculis stock sinks 23% after OCS-01 misses Phase 3 DME goal
- OCS-01 trial miss sends Oculis shares sharply lower intraday
- Oculis shifts pipeline focus after DME eye drop trials disappoint
- Oculis drops FDA filing plan as OCS-01 misses key vision target
- Strong cash runway supports Oculis after major Phase 3 setback
Oculis Holding AG (OCS) shares fell sharply after two late-stage diabetic macular edema studies missed their main vision target. OCS traded at $22.70, down $6.94, or 23.42%, after early stability near $29.65 faded. The update shifted focus from OCS-01 toward other late-stage programs across neuro-ophthalmology and eye disease.
OCS-01 Misses Main Vision Goal In Phase 3 Trials
Oculis reported topline results from the Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops. The company tested the treatment in patients with diabetic macular edema over 52 weeks. However, both trials missed the primary endpoint for mean change in best corrected visual acuity.
The DIAMOND program included two double-masked, randomized, multi-center Phase 3 studies. Together, the trials enrolled more than 800 patients across 119 research sites in the United States and other countries. The studies measured vision changes through BCVA ETDRS letter scores at Week 52.
OCS-01 showed a meaningful reduction in retinal thickness, but that result did not support the main vision goal. DIAMOND-2 showed sustained retinal thickness reduction at all visits versus vehicle. DIAMOND-1 showed similar reduction at all visits except Week 52.
Oculis Drops FDA Filing Plan For DME
Oculis said it does not plan to pursue an FDA regulatory filing for OCS-01 in diabetic macular edema at this time. The decision followed the missed primary endpoint and the missed key secondary endpoint. That key measure tracked the share of patients with at least a 15-letter gain in BCVA.
The company said OCS-01 remained well tolerated throughout the trials. It also reported no unexpected adverse events during the studies. Additionally, the overall safety profile matched results seen in earlier trials.
Chief Executive Officer Riad Sherif said the company felt disappointed that retinal thickness gains did not improve vision at Week 52. He also said Oculis would complete its review of the DIAMOND data. However, the company will now direct more resources toward its late-stage portfolio.
Oculis Shifts Focus To Privosegtor And Licaminlimab
Oculis plans to prioritize Privosegtor and Licaminlimab after the DIAMOND outcome. Privosegtor remains in the PIONEER registrational program for optic neuropathies. Meanwhile, Licaminlimab continues through the PREDICT-1 registrational trial for dry eye disease.
The company said its balance sheet supports the revised development plan. Oculis held $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026. That position provides a cash runway into the second half of 2029.
The stock reaction showed how strongly the market priced the failed DME target. OCS-01 had aimed to offer a non-invasive eye drop option for diabetic macular edema. However, Oculis will now lean on its remaining pipeline while it reviews the full trial data.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
